Professional Documents
Culture Documents
INTRODUCING
Project|21
HUMAN CLINICAL TRIALS FOR REJUVENATION BIOTECHNOLOGIES
Introducing Project|21
Through Project|21 we will be able to deliver human clinical trials of rejuvenation
biotechnologies by 2021.
Ending aging will require large-scale investment to flow into a globally-recognized industry for
rejuvenation biotechnology. We have put all the pieces in place core research groups, key players, shared
knowledge, underlying toolsfor the creation of this industry.
Now, through three new Foundation programs, Project|21 will deliver the perfect environment for the
critical marriage of opportunity and investment. With proper stewardship of this emerging industry, we
can create an environment where the first damage repair interventions addressing specific age-related
diseases will be brought to human clinical trials within five years.
Project|21 will require $50 million in total funding, at least half of which will come from the members of
SENS Research Foundations Group|21. Group|21 will bring together 21 philanthropists, each donating
between $500,000 and $5 million. Grants, grassroots efforts, and matching-fund strategies will provide the
remaining support.
Group|21:
L E A D E R S H I P, E N G A G E M E N T, P A R T N E R S H I P
Philanthropic giving should open a dialogue between donor and recipient which goes
beyond a financial transaction. Through engagement philanthropy we seek to develop
individual, tailored relationships with our Group|21 and other supporters, providing them
with the opportunity to integrate fully into our network, not just with regular e-mail
updates, but with regional meetings, project reviews, and investment analyses.
Project|21 has been carefully designed to pair this engagement philanthropy with the
strongest elements of venture philanthropy: flexible funding models, programs designed
to evolve into self-supporting efforts, and solid investment in core facilities. This hybrid
model is woven into the structure of the Project|21 programs.
Our leadership team knows that the decision to invest in a non-profit is not one made
l i g h t l y, a n d r e q u i r e s a p e r s o n a l r e l a t i o n s h i p b a s e d o n t r a n s p a r e n c y a n d t r u s t .
Michael Kope Chief Executive Officer and Co-founderreceived his J.D. from the University of Michigan in 1990. He has served
as the University of Michigans Intellectual Property Counsel, Director of Corporate Development for Aviron and MedImmune,
and CEO and officer of a number of biotechnology start-ups.
Aubrey de Grey, Ph.D. Chief Science Officer and Co-founderreceived his Ph.D. in Biology from the University of Cambridge
in 2000. He is Editor-in-Chief of Rejuvenation Research, is a Fellow of both the Gerontological Society of America and the
American Aging Association, and sits on the editorial and scientific advisory boards of numerous journals and organizations.
Michael and Aubrey are supported by the staff of SENS Research Foundation and by the twenty-six field-leading scientists on our
Research Advisory Board who help guide our research strategy.
Rejuvenation
Biotechnologies
Many things go wrong with aging bodies,
but at the root of them all is the burden
of decades of unrepaired damage to
the cellular and molecular structures
that make up the functional units of our
tissues.
In contrast, rejuvenation
biotechnologies are targeted therapies
that apply the principles of regenerative
medicine to the entire scope of the
damage of aging. These damage-
repair therapies will restore the normal
functioning of our bodies cells and
essential biomolecules, preventing age-
related disease.
Instead of merely slowing down the
accumulation of aging damage in our
tissues, rejuvenation biotechnologies
will remove, repair, replace or render
harmless our damaged cellular and
molecular machinery, returning aging
tissues to health.
SENS Research Foundation has always looked to a wide community for support for its
vision of a world free from the diseases of aging.
Today we look to you to join us in Project|21, as donors and partners. Contribute to our
strategic planning, board recruitment, capital programs, network growth, and expanding
industry networks.